ELDN
Eledon Pharmaceuticals, Inc.Company Information
- Company Name
- Eledon Pharmaceuticals, Inc.
- CIK
- CIK0001404281
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ELDN: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ELDN
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-05-09
- Last sale
- —
- Shares purchased (TTM)
- 1,927,937
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 46,847,104
- Shares outstanding
- 113,631,565
- Ownership
- 41.23%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- -18.38%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 7 | 6 | 23 | 4 | 6 | 8 | 21 | 7 | 26 | 6 | 5 | 4 | ||||||
| Short Term Investments | 82 | 105 | 111 | 90 | 102 | 116 | 120 | 71 | 58 | 37 | 46 | 56 | ||||||
| Prepaid Expense And Other Assets Current | 4 | 2 | 2 | 3 | 4 | 3 | 4 | 3 | 4 | 5 | 5 | 3 | ||||||
| Assets Current | 93 | 114 | 136 | 96 | 111 | 128 | 144 | 82 | 87 | 48 | 56 | 63 | ||||||
| Operating Lease Right Of Use Asset | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 126 | 147 | 169 | 130 | 145 | 161 | 177 | 115 | 120 | 81 | 89 | 96 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 3 | 7 | 4 | 5 | 6 | 3 | 6 | 6 | 2 | 2 | 1 | 0 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Accrued Liabilities And Other Liabilities | 8 | 7 | 14 | 9 | 8 | 6 | 5 | 6 | 4 | 2 | 3 | 2 | ||||||
| Liabilities Current | 12 | 13 | 18 | 14 | 14 | 9 | 12 | 12 | 6 | 4 | 4 | 3 | ||||||
| Deferred Income Tax Liabilities Net | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | - | 0 | 0 | ||||||
| Warrants And Rights Outstanding | 40 | 30 | 11 | 22 | 23 | 35 | 45 | 24 | 121 | - | 76 | 56 | ||||||
| Liabilities | 54 | 46 | 32 | 39 | 39 | 47 | 59 | 39 | 129 | 96 | 82 | 60 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 505 | 485 | 482 | 426 | 424 | 421 | 474 | 331 | 324 | 328 | 271 | 325 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | 0 | -0 | -0 | 0 | 0 | - | - | - | - | ||||||
| Retained Earnings Accumulated Deficit | -472 | -440 | -401 | -391 | -373 | -362 | -356 | -311 | -388 | -343 | -319 | -289 | ||||||
| Stockholders Equity | 33 | 45 | 81 | 35 | 50 | 59 | 62 | 20 | -64 | -70 | -48 | 36 | ||||||
| Liabilities And Stockholders Equity | 126 | 147 | 169 | 130 | 145 | 161 | 177 | 115 | 120 | 81 | 89 | 96 | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | - | - | - | - | - | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Temporary Equity Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | ||||||
| Temporary Equity Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | - | - | - | - | - | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 300 | 300 | 300 | 300 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 81 | 76 | 75 | 60 | 60 | 60 | 60 | 41 | 39 | 25 | 24 | 24 | ||||||
| Shares Outstanding | 81 | 76 | 75 | 60 | 60 | 60 | 60 | 41 | 39 | 25 | 24 | 24 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialEledon Pharmaceuticals, Inc. (ELDN) — SEC Financial Statements & Analysis
Eledon Pharmaceuticals, Inc. (ELDN) is a pharmaceutical preparations company, incorporated in DE. Eledon Pharmaceuticals, Inc. trades on Nasdaq as: ELDN. Eledon Pharmaceuticals, Inc. (ELDN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Eledon Pharmaceuticals, Inc. carries a market cap of $447.71M, a P/E ratio of -4.52x, a P/B ratio of 13.56x, an enterprise value of $440.91M, and an EV/EBITDA multiple of -5.85x. On profitability, it posts a Return on Equity (ROE) of -237.70%, a Return on Assets (ROA) of -73.10%, and a Return on Invested Capital (ROIC) of -212.96%. Per share, it reports EPS of $-0.87, diluted EPS of $-0.87, free cash flow per share of $-0.65, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -754.35% year-over-year and EPS growth of -544.31% year-over-year. On the balance sheet, it maintains a current ratio of 7.90x, a quick ratio of 7.53x, working capital of $81.30M, a debt-to-equity ratio of 1.64x, a debt ratio of 0.43, free cash flow of $-73.86M (TTM), and net debt of $-6.80M. Figures sourced from SEC EDGAR.
- Market Cap
- $447.71M
- P/E TTM
- -4.52x
- EPS TTM
- $-0.87
- P/B TTM
- 13.56x
- ROE TTM
- -237.70%
- ROA TTM
- -73.10%
- Debt To Equity
- 1.64x
- Free Cash Flow TTM
- $-73.86M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Eledon Pharmaceuticals, Inc. in?
Eledon Pharmaceuticals, Inc. (ELDN) operates in the Pharmaceutical Preparations industry.
What exchange does ELDN trade on?
Eledon Pharmaceuticals, Inc. (ELDN) trades on the Nasdaq.
Where is Eledon Pharmaceuticals, Inc. incorporated?
Eledon Pharmaceuticals, Inc. is incorporated in DE.
When was Eledon Pharmaceuticals, Inc. (ELDN)'s most recent SEC filing?
Eledon Pharmaceuticals, Inc. (ELDN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is ELDN's market cap?
Eledon Pharmaceuticals, Inc. (ELDN) has a market capitalization of $447.71M as of 2026-06-30.
What is ELDN's EPS (earnings per share)?
Eledon Pharmaceuticals, Inc. (ELDN)'s trailing twelve month EPS is $-0.87 as of 2026-06-30.
What is ELDN's ROE (return on equity)?
Eledon Pharmaceuticals, Inc. (ELDN)'s trailing twelve month Return on Equity (ROE) is -237.70% as of 2026-06-30.
What is ELDN's ROA (return on assets)?
Eledon Pharmaceuticals, Inc. (ELDN)'s trailing twelve month Return on Assets (ROA) is -73.10% as of 2026-06-30.
What is ELDN's ROIC (return on invested capital)?
Eledon Pharmaceuticals, Inc. (ELDN)'s trailing twelve month Return on Invested Capital (ROIC) is -212.96% as of 2026-06-30.
What is ELDN's EV/EBITDA?
Eledon Pharmaceuticals, Inc. (ELDN)'s trailing twelve month EV/EBITDA is -5.85x as of 2026-06-30.